IMMUNOME INC (IMNM) Stock Analyst Ratings
NASDAQ:IMNM - Nasdaq - US45257U1088 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 87% to IMNM. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 24.14. This target is 179.72% above the current price.
IMNM was analyzed by 15 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about IMNM.
In the previous month the buy percentage consensus was at a similar level.
IMNM was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-02 | Lake Street | Initiate | Buy |
| 2025-03-20 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-20 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-20 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-11 | LifeSci Capital | Initiate | Outperform |
| 2024-11-14 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-08 | Stephens & Co. | Initiate | Overweight |
| 2024-10-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-05-31 | Piper Sandler | Initiate | Overweight |
| 2024-04-30 | JP Morgan | Initiate | Overweight |
| 2024-04-15 | Guggenheim | Initiate | Buy |
| 2024-04-01 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-01-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-12-19 | Wedbush | Initiate | Outperform |
| 2023-03-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2023-03-17 | Chardan Capital | Maintains | Buy |
| 2021-10-29 | Cantor Fitzgerald | Initiate | Overweight |